· Published by Health Canada · Official notice
This is duplicated text of a letter from Amgen Canada, Inc., Abbott Laboratories, Ltd., and Schering Canada, Inc.
Contact the respective company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
January 13, 2006
Subject: Hepatitis B Reactivation associated with the anti-TNFα products ENBREL (etanercept), HUMIRA (adalimumab), and REMICADE (infliximab)
Dear Health Care Professional:
The manufacturers of the anti-TNFα products, in consultation with Health Canada, would like to inform you of updated safety information regarding anti-TNFα therapy. There are three (3) such products authorized for sale in Canada, and a summary of these products and their general indications is provided below:
| Brand Name | Manufacturer | Indication(s) |
|---|---|---|
| ENBREL (etanercept) | Immunex Corporation (Distributor: Amgen Canada, Inc.) |
Rheumatoid Arthritis Juvenile Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis Chronic Plaque Psoriasis |
| HUMIRA (adalimumab) | Abbott Laboratories, Ltd. | Rheumatoid Arthritis |
| REMICADE (infliximab) | Centocor, Inc. (Distributor: Schering Canada, Inc.) |
Rheumatoid Arthritis Crohn's Disease Ankylosing Spondylitis |
Based on review of recent post-marketing reports:
Very rare cases (less than 1 adverse event per 10,000 treated patients) of HBV reactivation associated with anti-TNFα therapy have been reported cumulatively, with one (1) report originating from Canada. Clinically active HBV infection occurred following a latency period ranging from 3 weeks to 20 months after initiation of therapy. In the majority of cases, patients were also being treated with other immunosuppressive drugs, including methotrexate, azathioprine, and/or corticosteroids. Hence, establishing a direct causal relationship to anti-TNFα agents is confounded by the presence of these other medications.
Where outcome information was provided, most patients were reported to have improved after antiviral treatment and/or discontinuation of the anti-TNFα agent. However, fatal outcomes have also occurred in reported cases.
The Canadian Product Monographs for ENBREL, HUMIRA, and REMICADE are being revised to include the above updated safety information.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of HBV reactivation or other serious or unexpected adverse reactions in patients receiving ENBREL, HUMIRA, or REMICADE should be reported to Amgen Canada, Inc., Abbott Laboratories, Ltd., or Schering Canada, Inc., respectively, or Health Canada at the following addresses:
ENBREL
Amgen Canada, Inc. (on behalf of Immunex Corporation)
6755 Mississauga Road, Suite 400
Mississauga, Ontario L5N 7Y2
Tel: (866) 512-6436
Fax: (888) 264-3655
HUMIRA
Abbott Laboratories, Limited
Medical Information Department
8401 Trans-Canada Highway
Saint-Laurent, Quebec H4S 1Z1
Tel : 1-800-567-2226
Fax : (514) 832-7824
REMICADE
Schering Canada, Inc. (on behalf of Centocor, Inc.)
3535 Trans-Canada Highway
Pointe Claire, Quebec, H9R 1B4
Tel: (800) 463-5442
Fax: (800) 369-3090
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
Your professional commitment in this regard has an important role in protecting the well being of your patients by contributing to early signal detection and informed drug use. A copy of this letter is also available on the Health Canada web site.
Sincerely Yours,
original signed by
Dr. Jose Iglesias
Medical Director,
Oncology
Amgen Canada
(on behalf of Immunex Corp.)
Mauricio Ede, MD, PhD
Medical Director
Abbott Laboratories, Ltd.
Jennifer Chan, MSc.
Director, Regulatory Affairs
Schering Canada, Inc.